Effects of Panax notoginseng saponins on the activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in rats in vivo

Phytotherapy Research

Volumn 26, Issue 8, 2012, Pages 1113-1118

  Liu, Rui ^a   Qin, Mengnan ^a   Hang, Pengzhou ^a   Liu, Yan ^a   Zhang, Zhiren ^a   Liu, Gaofeng ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

CYP1A2; CYP2C9; CYP2D6; CYP3A4; Panax notoginseng saponins

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAPSONE; METOPROLOL; SAPONIN DERIVATIVE; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HERB DRUG INTERACTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANAX NOTOGINSENG; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CAFFEINE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES; DAPSONE; ENZYME ACTIVATION; INJECTIONS, INTRAPERITONEAL; LIVER; MALE; METOPROLOL; PANAX NOTOGINSENG; PROTEIN BIOSYNTHESIS; RATS; RATS, WISTAR; SAPONINS; TANDEM MASS SPECTROMETRY; TIME FACTORS; TOLBUTAMIDE;

PANAX NOTOGINSENG; RATTUS;

EID: 84864283685     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3688     Document Type: Article

References (34)

1. Bai Y, Zhang SY, Ren J, et al,. 2001. Studies on Panax notoginseng saponins injection for treatment of cerebral infarction by multicenters. Chin J New Drugs Clin Rem 20: 257-259.
2. Bertilsson L, Carrillo JA, Dahl ML, et al,. 1994. Clozapine disposition covaries with CYP1A2 activity determined by caffeine test. Br J Pharmacol 38: 471-473.
3. Carrillo JA, Christensen M, Ramos S, et al,. 2000. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliv and urine. Ther Drug Monit 22: 409-417.
4. Chavez ML, Jordan MA, Chavez PI,. 2006. Evidence-based drug-herbal interactions. Life Sci 78: 2146-2157.
5. Cicero AFG, Bandieri E, Arletti R,. 2000. Orally administered Panax notoginseng influence on rat spontaneous behaviour. J Ethnopharmacol 73: 387-391.
6. Deborah AK, Dugald S,. 2010. Clinically based evidence of drug-herb interactions: systematic review. Expert Opin Drug Saf 9: 79-124.
7. Guengerich FP,. 1995. Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, Ortiz de Montellano PR, (ed.) Plenum Press: New York and London, 473-535.
8. Huang C, Gu TX, Guan YY, Wang JQ,. 1991. Effects of Panax notoginseng saponins on myocardial ischemi and reperfusion injury in conscious rabbit. Chin Pharmacol Bull 7: 190-193.
9. Huang YS, Yang ZC, Yan BG, Hu XC, L An, Crowther RS,. 1999. Improvement of early postburn cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation. Burns 25: 35-41.
10. Idani R, Marí TD, Nuri J, et al,. 2009. Inhibition of human P450 enzymes by natural extracts used in traditional medicine. Phytother Res 23: 279-282.
11. Lam SK, Ng TB,. 2001. Isolation of small chitinase-like antifungal protein from Panax notoginseng (sanchi ginseng) roots. Int J Biochem Cell Biol 33: 287-292.
12. Lam SK, Ng TB,. 2002. xylanase from roots of sanchi ginseng (Panax notoginseng) with inhibitory effects on human immunodeficiency virus-1 reverse transcriptase. Life Sci 70: 3049-3058.
13. Li LX, Wang ZC, Huang ZH, Zhang YM, Wei JX,. 1991. Effects of Panax notoginseng saponins on acute cerebral ischemia. Chin PharmacoI Bull 7: 56-59.
14. Li SH, Chu Y,. 1999. Anti-inflammatory effects of total saponins of Panax notoginseng. Act Pharmacol Sin 20: 551-554.
15. Li X, Chen JX, San JJ,. 1990. Protective effects of Panax notoginseng saponins on experimental myocardial injury induced by ischemi and reperfusion in rat. Act Pharmacol Sin 11: 26-29.
16. Li Y, Cheng YF, Gu BX,. 2006. Recent clinical application of Panax notoginseng saponins preparation. Chin Pharm 15: 57-58.
17. Liu Y, Xie MX, Kang J, Zheng D,. 2003. Studies on the interaction of total saponins of Panax notoginseng and human serum albumin by Fourier transform infrared spectroscopy. Spectrochim Act Mol Biomol Spectrosc 59: 2747-2758.
18. Li YW, Zhou XL,. 1991. Effects of Panax notoginseng saponins on hemorrhagic shock and cardial performance in rats. Chin J Pathophysiol 7: 298-300.
19. Nebert DW, Russell DW,. 2002. Clinical importance of the cytochromes P450. Lancet 360: 1155-1162.
20. Ng TB,. 2006. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 58: 1007-1019.
21. Otani K, Aoshim T,. 2000. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 22: 118-121.
22. Rendic S, Di Carlo FJ,. 1997. Human cytochrome P450 enzyme: status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 29: 413-580.
23. Rettie AE, Koop DR, Haining RL,. 2000. CYP2C. In Metabolic Drug interactions, Levy H, Thummel K, Trager W, Hansten P, Eichelbaum M, (eds). Lippincott Williams & Wilkins: New York, 75-86.
24. Shimad T, Yamazaki H, Mimur M, Inui Y, Guengerich FP,. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.
25. Spigset O, Hagg S, Soderstrom E, Dahlqvist R,. 1999. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur J Clin Pharmacol 54: 943-946.
26. Sun K, Wang CS, Guo J, et al,. 2007. Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci 81: 509-518.
27. Wrighton SA, Thummel KE,. 2000. CYP3A. In Metabolic Drug Interactions, Levy H, Thummel K, Trager W, Hansten P, Eichelbaum M, (eds). Lippincott Williams & Wilkins: New York, 115-134.
28. Wrighton SA, Vandenbranden M, Stevens JC, et al,. 1993. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25: 453-484.
29. Xiao P, Zhou HH,. 2008. Advance in cytochrome P450 1A2. J Cent South Univ (Med Sci) 335: 456-460.
30. Zanger U, Eichelbaum M,. 2000. CYP2D6. In Metabolic Drug Interactions, Levy H, Thummel K, Trager W, Hansten P, Eichelbaum M, (eds). Lippincott Williams & Wilkins: New York, 87-94.
31. Zhang L,. 2009. Research on the radix notoginseng total saponins dispersible tablets. Chin Licensed Pharmacist 6: 27-29.
32. Zhou JM, Ke JH, Cui XM, Wang CL, Yuan HL, Liang C,. 2003a. Study on preparation process for Xuesaitong dropping pills. Chin Tradit Patent Med 25: 787-789.
33. Zhou SF, Gao YH, Jiang WQ, Huang M, Xu AL, James WP,. 2003b. Interactions of herbs with cytochrome P450. Drug Metab Rev 35: 35-98.
34. Zhou SF, Huang M, Xu AL, Yang HY, Duan W, James WP,. 2005. Prediction of herb-drug metabolic interactions: simulation study. Phytother Res 19: 464-471.